Biotinylated Human HLA-A*11:01&B2M&KRAS (VVGAGGVGK) Complex Protein (Monomer, MALS verified)
分子別名（Synonym）
HLA-A*1101 | B2M | KRAS (VVGAGGVGK)
表達(dá)區(qū)間及表達(dá)系統(tǒng)（Source）
Biotinylated Human HLA-A*11:01&B2M&KRAS (VVGAGGVGK) Complex Protein (HLS-H82E3) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Thr 305 (HLA-A*11:01) & Ile 21 - Met 119 (B2M) & VVGAGGVGK peptide (Accession # Q5S3G3-1 (HLA-A*11:01) & P61769 (B2M) & VVGAGGVGK).
Predicted N-terminus: Gly 25 & Ile 21
蛋白結(jié)構(gòu)（Molecular Characterization）
Biotinylated Human HLA-A*11:01&B2M&KRAS (VVGAGGVGK) Complex Protein is produced by co-expression of HLA and B2M loaded with KRAS peptide.
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag?).
The protein has a calculated MW of 36.0 kDa and 11.7 kDa. The protein migrates as 40-45 kDa and 12 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
標(biāo)記（Labeling）
Biotinylation of this product is performed using Avitag? technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白標(biāo)記度（Protein Ratio）
Passed as determined by the HABA assay / binding ELISA.
內(nèi)毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
純度（Purity）
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景（Background）
Kirsten大鼠肉瘤2病毒癌基因同源物（KRAS）癌基因在胰腺腫瘤的發(fā)生和維持中起著關(guān)鍵作用，其信號網(wǎng)絡(luò)是治療干預(yù)的主要靶點。生物素化人HLA-A*1101 KRAS（VVGAGGVGK）復(fù)合物蛋白是KRAS MHC I類、B2M和VVGAGGVGA肽的HLA-A*101復(fù)合物。
關(guān)鍵字： HLA-A;HLA-A蛋白;HLA-A重組蛋白;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。